Financial Daily from THE HINDU group of publications
Wednesday, Apr 07, 2004
Financial Daily from THE HINDU group of publications Wednesday, Apr 07, 2004 |
||
|
|
||
|
Corporate
-
Announcements Marketing - Standards & Benchmarks Industry & Economy - Health Nicholas Piramal backs cough syrup quality Our Bureau
Mumbai , April 6 NICHOLAS Piramal India Ltd (NPIL) on Monday said it stood by the quality of its paediatric cough syrup, Tixylix. The company statement comes following recent media reports that the Delhi government's Drug Control Department had said the product was sub-standard. Further, the company added that it would contest the testing procedure adopted by the Ghaziabad-based laboratory of the Delhi Drug Control Department (DCD). NPIL officials told Business Line that the developments had happened 18 months ago, when the DCD's officials had tested products with one of NPIL's distributors. "The procedure used to test our product at the Ghaziabad laboratory is inappropriate. One requires sophisticated machinery to test the Codine element. Besides, we have not been show-caused till now by the Department," the NPIL official said. Significantly, the company points out: "Tixylix contains a controlled substance and is subject to strict testing by the drug administration in Gujarat, where it is manufactured. The Baroda laboratory of Gujarat FDA has tested the samples of the same product and reported it to be of `Standard Quality.'"
More Stories on : Announcements | Standards & Benchmarks | Health | Pharmaceuticals
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2004, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|